Health and Healthcare

Kodiak Sciences Announces Potential Pricing for IPO

Thinkstock

Kodiak Sciences has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 9.0 million shares in the range of $13 to $15 a piece, with an overallotment option for an additional 1.35 million shares. At the maximum value, the entire offering is valued up to $155.25 million. The company intends to list its shares on the Nasdaq under the symbol KOD.

The underwriters for the offering are Morgan Stanley, Merrill Lynch, Barclays and Chardan.

This is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Its most advanced product candidate is KSI-301, a biologic therapy built with its antibody biopolymer conjugate (ABC) platform, which is designed to maintain potent and effective drug levels in ocular tissues.

Management believes that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration (wet AMD), and diabetic retinopathy (DR). KSI-301 and the ABC Platform were developed at Kodiak, and the firm owns worldwide rights to those assets, including composition of matter patent protection for KSI-301.

Kodiak has applied its ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate. Management intends to progress these and other product candidates to address high-prevalence ophthalmic diseases.

The company detailed its plans for the net proceeds in the filing as follows:

  • To advance KSI-301 through enrollment of the Phase 2 clinical trial in the U.S., EU and rest of the world in patients with wet AMD and to expand the scope of our Phase 1 clinical trial for KSI-301 through completion of a Phase 1b clinical trial;
  • To advance KSI-301 into Phase 2 clinical trials in China for wet AMD and DME/DR;
  • To advance KSI-301 into the Phase 2 clinical trial in the U.S., EU and rest of the world in patients with DME/DR;
  • Towards research and development of our pipeline including KSI-501, and to initiate additional clinical studies in ophthalmology; and
  • The remainder for working capital and other general corporate purposes.

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.